Treatment of infantile fibrosarcoma associated to an abdominal aortic aneurysm with larotrectinib: a case report.

Autor: Corral Sánchez MD; Pediatric Hematology and Oncology Service, University Hospital La Paz, Madrid, Spain., Galán Gómez V; Pediatric Hematology and Oncology Service, University Hospital La Paz, Madrid, Spain., Sastre Urgelles A; Pediatric Hematology and Oncology Service, University Hospital La Paz, Madrid, Spain., Plaza López de Sabando D; Pediatric Hematology and Oncology Service, University Hospital La Paz, Madrid, Spain., Rubio Aparicio P; Pediatric Hematology and Oncology Service, University Hospital La Paz, Madrid, Spain., Martínez Martínez L; Pediatric Surgery Service, University Hospital La Paz, Madrid, Spain., Alonso Gamarra E; Pediatric Radiology Service, University Hospital La Paz, Madrid, Spain., Pozo Kreilinger JJ; Anathomical Pathology Service, University Hospital La Paz, Madrid, Spain., Regojo Zapata RM; Anathomical Pathology Service, University Hospital La Paz, Madrid, Spain., López Gutiérrez JC; Vascular Congenital Anomalies Unit, University Hospital La Paz, Madrid, Spain., Antolín Alvarado E; Obstetrics & Gynecology Service, University Hospital La Paz, Madrid, Spain., Gómez Martín F; Neonatology Service, University Hospital La Paz, Madrid, Spain., Sánchez Torres AM; Vascular Surgery Service, University Hospital La Paz, Madrid, Spain., Marín Manzano E; Pharmacy Service, University Hospital La Paz, Madrid, Spain., González Del Valle L; Pharmacy Service, University Hospital La Paz, Madrid, Spain., Pérez-Martínez A; Pediatric Hematology and Oncology Service, University Hospital La Paz, Madrid, Spain.; Universidad Autónoma de Madrid, Madrid, Spain.
Jazyk: angličtina
Zdroj: Pediatric hematology and oncology [Pediatr Hematol Oncol] 2021 Aug; Vol. 38 (5), pp. 504-509. Date of Electronic Publication: 2021 Feb 24.
DOI: 10.1080/08880018.2021.1889730
Abstrakt: Infantile fibrosarcoma (IFS) is a rare pediatric tumor which often presents the ETV6-NTRK3 gene fusion. NTRK3 encodes the neurotrophin-3 growth factor receptor tyrosine kinase, a druggable therapeutic target. Selective tropomyosin receptor kinase (TRK) inhibitors, such as larotrectinib, have shown efficacy and safety in the treatment of IFS. We report a case of an abdominal IFS diagnosed in a newborn associated with an aortic aneurysm that was successfully treated with larotrectinib without relevant adverse effects.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje